leon-nanodrugs GmbH and Bionpharma Inc. said yesterday that the 2 groups inked a deal to develop a dermatological product using leon-nanodrugs’ microjet reactor nanotechnology platform.
The companies will share the development of the undisclosed product. Development will be done at leon-nanodrugs’ U.S.-based formulation partner CoreRx in Clearwater, Florida. Bionpharma will market and distribute the product in the U.S. and other markets.
leon-nanodrugs’ microjet reactor technology is used to reformulate active pharmaceutical ingredients that are poorly soluble in water. The company touts its 1-step process as highly cost effective and easily scalable.
“We are very pleased about the partnership with Bionpharma who share our vision to generate added value to therapeutic molecules through the unique attributes of our MicroJet Reactor Technology,” leon-nanodrugs CEO Michael Mehler said in prepared remarks. “In addition this co-development is a key strategic step on our way to become a recognized global leader in nanotechnology formulated pharmaceuticals.”
“Bionpharma strives to bring uniquely formulated products to the market and this association with leon-nanodrugs is a big step towards this endeavor,” Bionpharma president & CEO Venkat Krishnan added.
